We found that 8 out of 10 aplastic anemia patients experienced resolution of platelet transfusion refractoriness following daratumumab administration. Notably, 4 responders achieved hematopoietic recovery, including 3 participants showed improvements in multi-lineage blood cell counts, even with daratumumab monotherapy (NCT05832216).

Subjects:
Clinical Trials and Observations
This content is only available as a PDF.
Copyright © 2025 American Society of Hematology
2025

Article PDF first page preview

First page of Targeting CD38 with Daratumumab for Platelet Transfusion Refractoriness in Aplastic Anemia
You do not currently have access to this content.
Sign in via your Institution